Kenvue Inc.
https://www.jnj.com/kenvue
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kenvue Inc.
J&J Tees Up Proposal To Settle Complaints Alleging Talc Caused Ovarian Cancer
J&J executives are confident the proposal to pay plaintiffs making ovarian cancer claims a total of $6.48bn over 25 years will be accepted, resolving 99.75% of those lawsuits pending against it and US affiliates. The proposal allows individual plaintiffs direct say on whether to accept it.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice